Aligos Therapeutics Inc. (ALGS) Announces James Scopa to Board

Aligos Therapeutics, Inc. (NASDAQ: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that the company has appointed James Scopa, J.D., MBA, to the Company’s board of directors.

“We are thrilled to add someone of Jim’s experience and accomplishments to Aligos’ board, as the company continues its arc from its earliest, private, preclinical phase to growing into its role as an established clinical-stage public biopharma company,” said Aligos Chief Executive Officer Lawrence Blatt, Ph.D., MBA. “Aligos will look to Jim for strategic counsel as the company approaches mid-stage clinical trials in chronic hepatitis B. We believe that Jim, with his extensive industry experience and his service as a director for numerous companies, will make a welcome addition to our board.”

Mr. Scopa brings over 30 years of experience in the life sciences industry as an investor and an advisor, having guided public and private boards on strategic and financial transactions. He currently serves as a member of the Investment Advisory Committee and Advisory Board of One Ventures, an Australia-based venture capital firm; he also holds board positions with several biotechnology companies, including Neuron 23 Inc., DiCE Molecules, Blade Therapeutics, Inc., and Adverum Biotechnologies, Inc. Previously, Mr. Scopa served as a Managing Director of MPM Capital from May 2005 to June 2017; he spent the prior 15 years working at Deutsche Banc Alex. Brown and Thomas Weisel Partners, advising growth companies in biopharmaceuticals and medical devices. At Deutsche Banc Alex. Brown, Mr. Scopa served as Managing Director and Global Co-Head of Healthcare Investment Banking; at Thomas Weisel Partners, Mr. Scopa served on the Investment Committee for the company’s health care venture fund as well as Co-Director of Healthcare Investment Banking.

Mr. Scopa added, “Aligos, with its esteemed management team and commitment to the utmost scientific rigor, has positioned itself to be a leader in chronic hepatitis B and other liver and viral diseases. I am privileged to help guide the company’s vision with respect to clinical development as Aligos advances its programs.”

Mr. Scopa holds an A.B. from Harvard College, an M.B.A. from Harvard Business School and a J.D. from Harvard Law School.

You May Also Be Interested In

• Parabilis Medicines adds former J&J oncology executive to board
• TVS Motor names Peyman Kargar as CEO, effective January 2027
• Trinity Capital names Matt Nuyen director of originations for equipment finance